Glenmark Pharmaceuticals Inc., USA: Drug Recall

Recall #D-0430-2024 · 03/26/2024

Class II: Risk

Recall Details

Recall Number: D-0430-2024
Classification: Class II
Product Type: Drug
Recalling Firm: Glenmark Pharmaceuticals Inc., USA
Status: Ongoing
Date Initiated: 03/26/2024
Location: Mahwah, NJ, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 6,528 bottles

Reason for Recall

Failed Dissolution Specifications: Out of Specification (OOS) was reported in test of dissolution at the 12th month time point in long term stability study.

Product Description

Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg, Twice-a-Day Dosage, 100 Capsules per bottle, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ, 07430, Product of India, NDC 68462-562-01

Distribution Pattern

Nationwide in the US

Other Recalls by Glenmark Pharmaceuticals Inc., USA

Class II: Risk 12/30/2025

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.
Class III: Low Risk 11/21/2025

Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe
Class III: Low Risk 11/18/2025

Cross Contamination with Other Products
Class II: Risk 09/17/2025

CGMP Deviations: Market complaints received for gritty texture (grainy)
Class II: Risk 09/03/2025

Failed Impurities/Degradation Specifications

View all recalls by Glenmark Pharmaceuticals Inc., USA →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.